Alogliptin, a DPP-4 inhibitor, improves coronary flow reserve (CFR) and LVEF in patients with T2DM with coronary artery disease (CAD), and the improvement in CFR was associated with increased LV systolic function [12]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.